mouse anti human clec10a cd301 conjugated  (R&D Systems)

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: Three lectins, Galectin-4 C, Galectin-8 C, and CLEC10A-Fc, were extracted as candidate human endogenous lectins that recognize pancreatic cancer cells. ( a ) Among the 43 lectins, pancreatic cancer-reactive lectins were screened using flow cytometry. The difference (ΔMFI) between the median fluorescence intensity (MFI) of each lectin and the MFI of the control is shown in the heat map. Red arrows indicate lectins that met the criteria of MFI greater than 10 4 for the pancreatic cancer cell lines, Capan-1 or AsPC-1, and less than 10 4 for the pancreatic ductal cell line, hTERT-HPNE. ( b ) Histograms of Galectin-4 C, Galectin-8 C, and CLEC10A-Fc. The gray-filled histogram indicates control cells stained with PE-labeled BSA (for galectins) or PE-labeled anti-Fc antibody (for C-type lectins) used as negative controls, and the cyan line is the histogram of cells incubated with PE-labeled galectins or C-type lectins followed by PE-labeled anti-Fc antibody.

Article Snippet: Sections were blocked using peroxidase blocking solution (Agilent; Cat# K8000) for 5 min, washed in wash buffer, and incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene, Rockville, MD, USA; Cat# TA810180) for 20 min.

Techniques: Flow Cytometry, Fluorescence, Control, Staining, Labeling, Incubation

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A is a human endogenous lectin with high affinity for pancreatic cancer cells. ( a ) Representative images of pancreatic cancerous and noncancerous tissues stained with three lectins (Galectin-4 C, Galectin-8 C, and CLEC10A-Fc). Scale bars, 10 μm. The arrowhead (▼) indicates the positive staining of the cell membrane. ( b ) Percentage of cases positive for lectin staining in pancreatic cancer cells (C) and pancreatic duct cells (N) in noncancerous tissue compared using Fisher’s exact test (NS: not significant, * P < 0.05).

Article Snippet: Sections were blocked using peroxidase blocking solution (Agilent; Cat# K8000) for 5 min, washed in wash buffer, and incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene, Rockville, MD, USA; Cat# TA810180) for 20 min.

Techniques: Staining, Membrane

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A ligand is expressed in 60% of clinical pancreatic cancer cells. ( a ) Representative images of histochemically processed sections of clinical pancreatic cancer tissue analyzed for CLEC10A-Fc staining. Scale bars (Large window) 200 μm, (Small window) 10 μm. Staining intensity was scored according to the percentage of positive cells regardless of staining intensity as follows: 0, 0%; 1+, < 1%; 2+, 1–24; 3+, 25–49%; 4+, 50–74%; 5+, 75–100%. ( b ) A pie chart showing the percentage of each staining score in 113 processed sections of clinical pancreatic cancer tissue stained with CLEC10A-Fc.

Article Snippet: Sections were blocked using peroxidase blocking solution (Agilent; Cat# K8000) for 5 min, washed in wash buffer, and incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene, Rockville, MD, USA; Cat# TA810180) for 20 min.

Techniques: Staining

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A-expressing monocytic cells in pancreatic cancer stroma. ( a ) Left: Hematoxylin and eosin staining of representative pancreatic cancer tissue. Scale bars, 50 μm. Right: Immunostaining with anti-CLEC10A antibody in representative pancreatic cancer tissue. Scale bars, 50 μm. Cancer duct structures are surrounded by dotted lines (---); CLEC10A-expressing cells are indicated by arrowheads (▼). ( b ) Immunofluorescence staining of CLEC10A (red), CD163 (green), and nuclei (blue) in pancreatic cancer tissue; merge: yellow. Scale bars, 50 μm.

Article Snippet: Sections were blocked using peroxidase blocking solution (Agilent; Cat# K8000) for 5 min, washed in wash buffer, and incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene, Rockville, MD, USA; Cat# TA810180) for 20 min.

Techniques: Expressing, Staining, Immunostaining, Immunofluorescence

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: Appearance of CLEC10A-expressing monocytic cells and coexistence of CLEC10A ligand on pancreatic cancer cells are poor prognostic factors in stage II and III cases. ( a ) Representative images of formalin-fixed paraffin-embedded (FFPE) sections of clinical pancreatic cancer tissues stained with anti-CLEC10A antibody. Scale bars, 100 μm. Staining intensity was scored according to the number of positive cells in the 20× field of view as follows: 0 (0 fields); 1+ (1–2 fields); 2+ (> 3 fields). ( b ) Classification based on the combination of CLEC10A and CLEC10A ligand expression intensity. ( c ) Kaplan–Meier curve comparing category Low ( n = 23) with category High ( n = 5). Log-rank test (* P < 0.05) was used.

Article Snippet: Sections were blocked using peroxidase blocking solution (Agilent; Cat# K8000) for 5 min, washed in wash buffer, and incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene, Rockville, MD, USA; Cat# TA810180) for 20 min.

Techniques: Expressing, Formalin-fixed Paraffin-Embedded, Staining

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: Three lectins, Galectin-4 C, Galectin-8 C, and CLEC10A-Fc, were extracted as candidate human endogenous lectins that recognize pancreatic cancer cells. ( a ) Among the 43 lectins, pancreatic cancer-reactive lectins were screened using flow cytometry. The difference (ΔMFI) between the median fluorescence intensity (MFI) of each lectin and the MFI of the control is shown in the heat map. Red arrows indicate lectins that met the criteria of MFI greater than 10 4 for the pancreatic cancer cell lines, Capan-1 or AsPC-1, and less than 10 4 for the pancreatic ductal cell line, hTERT-HPNE. ( b ) Histograms of Galectin-4 C, Galectin-8 C, and CLEC10A-Fc. The gray-filled histogram indicates control cells stained with PE-labeled BSA (for galectins) or PE-labeled anti-Fc antibody (for C-type lectins) used as negative controls, and the cyan line is the histogram of cells incubated with PE-labeled galectins or C-type lectins followed by PE-labeled anti-Fc antibody.

Article Snippet: Samples were pre-incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene; Cat# TA810180) and Alexa Fluor 488-conjugated rabbit anti-CD163 monoclonal antibody (1:500, clone EPR19518 , Abcam, Cambridge, UK; Cat# AB313665 ) at room temperature for 30 min.

Techniques: Flow Cytometry, Fluorescence, Control, Staining, Labeling, Incubation

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A is a human endogenous lectin with high affinity for pancreatic cancer cells. ( a ) Representative images of pancreatic cancerous and noncancerous tissues stained with three lectins (Galectin-4 C, Galectin-8 C, and CLEC10A-Fc). Scale bars, 10 μm. The arrowhead (▼) indicates the positive staining of the cell membrane. ( b ) Percentage of cases positive for lectin staining in pancreatic cancer cells (C) and pancreatic duct cells (N) in noncancerous tissue compared using Fisher’s exact test (NS: not significant, * P < 0.05).

Article Snippet: Samples were pre-incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene; Cat# TA810180) and Alexa Fluor 488-conjugated rabbit anti-CD163 monoclonal antibody (1:500, clone EPR19518 , Abcam, Cambridge, UK; Cat# AB313665 ) at room temperature for 30 min.

Techniques: Staining, Membrane

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A ligand is expressed in 60% of clinical pancreatic cancer cells. ( a ) Representative images of histochemically processed sections of clinical pancreatic cancer tissue analyzed for CLEC10A-Fc staining. Scale bars (Large window) 200 μm, (Small window) 10 μm. Staining intensity was scored according to the percentage of positive cells regardless of staining intensity as follows: 0, 0%; 1+, < 1%; 2+, 1–24; 3+, 25–49%; 4+, 50–74%; 5+, 75–100%. ( b ) A pie chart showing the percentage of each staining score in 113 processed sections of clinical pancreatic cancer tissue stained with CLEC10A-Fc.

Article Snippet: Samples were pre-incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene; Cat# TA810180) and Alexa Fluor 488-conjugated rabbit anti-CD163 monoclonal antibody (1:500, clone EPR19518 , Abcam, Cambridge, UK; Cat# AB313665 ) at room temperature for 30 min.

Techniques: Staining

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: CLEC10A-expressing monocytic cells in pancreatic cancer stroma. ( a ) Left: Hematoxylin and eosin staining of representative pancreatic cancer tissue. Scale bars, 50 μm. Right: Immunostaining with anti-CLEC10A antibody in representative pancreatic cancer tissue. Scale bars, 50 μm. Cancer duct structures are surrounded by dotted lines (---); CLEC10A-expressing cells are indicated by arrowheads (▼). ( b ) Immunofluorescence staining of CLEC10A (red), CD163 (green), and nuclei (blue) in pancreatic cancer tissue; merge: yellow. Scale bars, 50 μm.

Article Snippet: Samples were pre-incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene; Cat# TA810180) and Alexa Fluor 488-conjugated rabbit anti-CD163 monoclonal antibody (1:500, clone EPR19518 , Abcam, Cambridge, UK; Cat# AB313665 ) at room temperature for 30 min.

Techniques: Expressing, Staining, Immunostaining, Immunofluorescence

Journal: Scientific Reports

Article Title: Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma

doi: 10.1038/s41598-025-02404-1

Figure Lengend Snippet: Appearance of CLEC10A-expressing monocytic cells and coexistence of CLEC10A ligand on pancreatic cancer cells are poor prognostic factors in stage II and III cases. ( a ) Representative images of formalin-fixed paraffin-embedded (FFPE) sections of clinical pancreatic cancer tissues stained with anti-CLEC10A antibody. Scale bars, 100 μm. Staining intensity was scored according to the number of positive cells in the 20× field of view as follows: 0 (0 fields); 1+ (1–2 fields); 2+ (> 3 fields). ( b ) Classification based on the combination of CLEC10A and CLEC10A ligand expression intensity. ( c ) Kaplan–Meier curve comparing category Low ( n = 23) with category High ( n = 5). Log-rank test (* P < 0.05) was used.

Article Snippet: Samples were pre-incubated with mouse anti-human CLEC10A monoclonal antibody (1:500, clone OTI2B10, OriGene; Cat# TA810180) and Alexa Fluor 488-conjugated rabbit anti-CD163 monoclonal antibody (1:500, clone EPR19518 , Abcam, Cambridge, UK; Cat# AB313665 ) at room temperature for 30 min.

Techniques: Expressing, Formalin-fixed Paraffin-Embedded, Staining